Developments in the field of antidepressants, where do we go now?

@article{Artigas2015DevelopmentsIT,
  title={Developments in the field of antidepressants, where do we go now?},
  author={F. Artigas},
  journal={European Neuropsychopharmacology},
  year={2015},
  volume={25},
  pages={657-670}
}
  • F. Artigas
  • Published 2015
  • Psychology, Medicine
  • European Neuropsychopharmacology
  • Major depression is a severe psychiatric syndrome with very high prevalence and socio-economic impact. Its pathophysiology is poorly known, yet several neurotransmitter systems and brain areas have been implicated. Selective serotonin (5-hydroxytryptamine, 5-HT) reuptake inhibitors (SSRI) and serotonin and norepinephrine reuptake inhibitors (SNRI) are most used antidepressant treatments. However, these drugs show slow onset of action and limited efficacy, making necessary the use of drug… CONTINUE READING
    66 Citations
    Functional Selectivity and Antidepressant Activity of Serotonin 1A Receptor Ligands
    • 49
    • Highly Influenced
    • PDF
    Monoaminergic and Histaminergic Strategies and Treatments in Brain Diseases
    • 24
    • PDF

    References

    SHOWING 1-10 OF 149 REFERENCES
    Serotonin receptors involved in antidepressant effects.
    • 211
    • PDF
    Effect of a single dose of escitalopram on serotonin concentration in the non-human and human primate brain.
    • 68
    • PDF
    Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors.
    • 501
    • PDF
    The 5-HT7 receptor and disorders of the nervous system: an overview
    • P. Hedlund
    • Psychology, Medicine
    • Psychopharmacology
    • 2009
    • 205
    A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
    • 2,388
    • PDF
    Synergistic Action of 5-HT2A Antagonists and Selective Serotonin Reuptake Inhibitors in Neuropsychiatric Disorders
    • 232
    • PDF
    Neurobiology of Depression
    • 1,406
    • PDF
    Emerging drugs for major depressive disorder
    • 54
    Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders.
    • 373
    • PDF
    Serotonin4 (5-HT4) Receptor Agonists Are Putative Antidepressants with a Rapid Onset of Action
    • 269